Nuclear imaging of neuroinflammation: a comprehensive challengers

European Journal of Nuclear Medicine and Molecular Imaging 35, 2304-2319

DOI: 10.1007/s00259-008-0908-9

Citation Report

#	Article	IF	CITATIONS
1	Initial Evaluation of $\langle \sup 11 \langle \sup C-DPA-713 \rangle$ , a Novel TSPO PET Ligand, in Humans. Journal of Nuclear Medicine, 2009, 50, 1276-1282.	5.0	117
2	PET of Glial Metabolism Using 2- <sup>18</sup> F-Fluoroacetate. Journal of Nuclear Medicine, 2009, 50, 982-990.	5.0	42
3	Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography. Current Medicinal Chemistry, 2009, 16, 2899-2923.	2.4	123
4	Comparative Evaluation of the Translocator Protein Radioligands <sup>11</sup> C-DPA-713, <sup>18</sup> F-DPA-714, and <sup>11</sup> C-PK11195 in a Rat Model of Acute Neuroinflammation. Journal of Nuclear Medicine, 2009, 50, 468-476.	5.0	208
5	2- <sup>18</sup> F-Fluoroacetate: A Useful Tool for Assessing Gliosis in the Central Nervous System?. Journal of Nuclear Medicine, 2009, 50, 841-843.	5.0	4
6	Multimodal microglia imaging of fiber tracts in acute subcortical stroke. Annals of Neurology, 2009, 66, 825-832.	5.3	56
7	Evaluation of <i>N</i> â€benzylâ€ <i>N</i> â€{ <sup>11</sup> C]methylâ€2― (7â€methylâ€8â€oxoâ€2â€phenylâ€7,8â€dihydroâ€9Hâ€purinâ€9â€yl)acetamide ([ <sup>11</sup> C]DAC) as protein (18 kDa) radioligand in kainic acidâ€lesioned rat. Synapse, 2009, 63, 961-971.	a nowel tra	ins <b>k</b> ocator
8	[18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1707-1710.	2.2	35
9	Advances in the molecular imaging of multiple sclerosis. Expert Review of Clinical Immunology, 2009, 5, 765-777.	3.0	7
11	Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 606-612.	6.4	39
12	In vivo imaging of neuroinflammation: a comparative study between [18F]PBR111, [11C]CLINME and [11C]PK11195 in an acute rodent model. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 962-972.	6.4	67
13	PET tracers for the peripheral benzodiazepine receptor and uses thereof. Drug Discovery Today, 2010, 15, 933-942.	6.4	66
14	The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned?. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 501-510.	1.0	11
15	Radiosynthesis of 7â€chloroâ€ <i>N</i> , <i>N</i> å€dimethylâ€5â€{ <sup>11</sup> C]methylâ€4â€oxoâ€3â€phenylâ€3,5â€dihydro [ <sup>11</sup> C]SSR180575, a novel radioligand for imaging the TSPO (peripheral benzodiazepine) Tj ETQq1	oâ€4≾i>H≀ 1 0.78431	:/i>â€pyrida <mark>zi</mark> 4 rgBT /Overk
16	Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorganic and Medicinal Chemistry, 2010, 18, 5202-5207.	3.0	93
17	New iodinated quinoline-2-carboxamides for SPECT imaging of the translocator protein. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 954-957.	2.2	19
18	lmaging of the translocator protein (18kDa) in rat brain after ischemia using [ <sup>11</sup> C]DAC with ultraâ€high specific activity. Synapse, 2010, 64, 488-493.	1.2	13
19	Evaluation of the PBR/TSPO Radioligand [ <sup>18</sup> F]DPA-714 in a Rat Model of Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 230-241.	4.3	184

#	Article	IF	Citations
20	Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews Drug Discovery, 2010, 9, 971-988.	46.4	774
21	Molecular imaging of major depression. , 0, , 170-196.		0
22	Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, <sup>18</sup> F-PBRO6, to Image Translocator Protein (18 kDa). Journal of Nuclear Medicine, 2010, 51, 145-149.	5.0	42
23	<sup>18</sup> F-FEAC and <sup>18</sup> F-FEDAC: PET of the Monkey Brain and Imaging of Translocator Protein (18 kDa) in the Infarcted Rat Brain. Journal of Nuclear Medicine, 2010, 51, 1301-1309.	5.0	51
24	Radioisotopic Imaging of Neuroinflammation: FIGURE 1 Journal of Nuclear Medicine, 2010, 51, 1-4.	5.0	74
25	SPECT and PET in Atypical Parkinsonism. PET Clinics, 2010, 5, 65-74.	3.0	0
26	The Temporal Dynamics of Poststroke Neuroinflammation: A Longitudinal Diffusion Tensor Imaging–Guided PET Study with ⟨sup⟩11⟨/sup⟩C-PK11195 in Acute Subcortical Stroke. Journal of Nuclear Medicine, 2010, 51, 1404-1412.	5.0	129
28	Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis, 2010, 210, 388-391.	0.8	83
29	<sup>89</sup> Zr-Labeled Dextran Nanoparticles Allow in Vivo Macrophage Imaging. Bioconjugate Chemistry, 2011, 22, 2383-2389.	3.6	116
30	Differential Expression of the 18 kDa Translocator Protein (TSPO) by Neoplastic and Inflammatory Cells in Mouse Tumors of Breast Cancer. Molecular Pharmaceutics, 2011, 8, 823-832.	4.6	37
31	Synthesis and Evaluation of Novel Carbon-11 Labeled Oxopurine Analogues for Positron Emission Tomography Imaging of Translocator Protein (18 kDa) in Peripheral Organs. Journal of Medicinal Chemistry, 2011, 54, 6040-6049.	6.4	11
32	Imaging of Atherosclerosis. Annual Review of Medicine, 2011, 62, 25-40.	12.2	101
33	Evaluation of Novel $\langle i \rangle N \langle  i \rangle \langle \sup \rangle 1 \langle  \sup \rangle$ . Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. Journal of Medicinal Chemistry, 2011, 54, 366-373.	6.4	25
34	Global-two-stage filtering of clinical PET parametric maps: Application to [11C]-(R)-PK11195. NeuroImage, 2011, 55, 942-953.	4.2	8
35	Age and disease related changes in the translocator protein (TSPO) system in the human brain: Positron emission tomography measurements with [11C]vinpocetine. Neurolmage, 2011, 56, 1111-1121.	4.2	80
36	Molecular tracers for the PET and SPECT imaging of disease. Chemical Society Reviews, 2011, 40, 149-162.	38.1	295
37	Functional Neuroimaging in Geriatric Depression. Psychiatric Clinics of North America, 2011, 34, 403-422.	1.3	17
38	Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO). Steroids, 2011, 76, 1331-1340.	1.8	58

3

#	Article	IF	CITATIONS
39	A rapid solid-phase extraction method for measurement of non-metabolised peripheral benzodiazepine receptor ligands, [18F]PBR102 and [18F]PBR111, in rat and primate plasma. Nuclear Medicine and Biology, 2011, 38, 137-148.	0.6	15
40	Positron emission tomography imaging in multiple sclerosis–current status and future applications. European Journal of Neurology, 2011, 18, 226-231.	3.3	28
41	Synthesis of 6-[18F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4819-4822.	2.2	28
42	New Fluorescent Probes Targeting the Mitochondrial-Located Translocator Protein 18ÂkDa (TSPO) as Activated Microglia Imaging Agents. Pharmaceutical Research, 2011, 28, 2820-2832.	3.5	22
43	Apoptosis Inhibition Can Be Threatening in A $\hat{I}^2$ -Induced Neuroinflammation, Through Promoting Cell Proliferation. Neurochemical Research, 2011, 36, 39-48.	3.3	39
44	Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [18F]DPA-714. Molecular Imaging and Biology, 2011, 13, 10-15.	2.6	63
45	Comparison of 18F- and 11C-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 352-357.	6.4	33
46	In vivo imaging of neuroinflammation in the rodent brain with [11C]SSR180575, a novel indoleacetamide radioligand of the translocator protein (18ÂkDa). European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 509-514.	6.4	51
47	Regional sensitivity to neuroinflammation: In vivo and in vitro studies. Synapse, 2011, 65, 634-642.	1.2	18
48	Imaging Brain Microglial Activation Using Positron Emission Tomography and Translocator Protein-Specific Radioligands. International Review of Neurobiology, 2011, 101, 19-39.	2.0	75
49	Towards molecular imaging of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 262-272.	3.0	11
50	Imaging of Microglia Activation in Stroke. Stroke, 2011, 42, 507-512.	2.0	111
51	Quantitative, Preclinical PET of Translocator Protein Expression in Glioma Using $\sup 18 < \sup F - i \le i$	5.0	57
52	Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans. Journal of Nuclear Medicine, 2012, 53, 330-335.	5.0	23
53	The neurobiology of Alzheimer disease defined by neuroimaging. Current Opinion in Neurology, 2012, $25, 1.$	3.6	31
54	Reactive Astrocytes Overexpress TSPO and Are Detected by TSPO Positron Emission Tomography Imaging. Journal of Neuroscience, 2012, 32, 10809-10818.	3.6	286
55	The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology. Current Molecular Medicine, 2012, 12, 356-368.	1.3	0
56	Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?. Current Molecular Medicine, 2012, 12, 387-397.	1.3	0

#	ARTICLE	IF	CITATIONS
57	Noninvasive Molecular Imaging of Neuroinflammation. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1393-1415.	4.3	216
58	An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1-5.	4.3	642
59	Molecular imaging of inflammation for detection of vulnerable atheromatous plaques. European Heart Journal, 2012, 33, 1857-1860.	2.2	2
60	Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor. Current Medical Imaging, 2012, 8, 302-307.	0.8	2
61	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. Advances in Biological Psychiatry, 2012, , 80-114.	0.2	0
62	Imaging of microglia in patients with neurodegenerative disorders. Frontiers in Pharmacology, 2012, 3, 96.	3.5	98
63	Translocator protein (18ÂkDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 107-112.	3.2	49
64	Comparison of 18F-fluoro-deoxy-glucose, 18F-fluoro-methyl-choline, and 18F-DPA714 for positron-emission tomography imaging of leukocyte accumulation in the aortic wall of experimental abdominal aneurysms. Journal of Vascular Surgery, 2012, 56, 765-773.	1.1	27
65	Solution Structures of the Prototypical 18 kDa Translocator Protein Ligand, PK 11195, Elucidated with <sup>1</sup> H/ <sup>13</sup> C NMR Spectroscopy and Quantum Chemistry. ACS Chemical Neuroscience, 2012, 3, 325-335.	3.5	17
66	Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology, 2012, 62, 2154-2168.	4.1	248
67	Radiation dosimetry of the translocator protein ligands [18F]PBR111 and [18F]PBR102. Nuclear Medicine and Biology, 2012, 39, 742-753.	0.6	11
68	Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans. Brain Research Bulletin, 2012, 87, 154-171.	3.0	39
69	<sup>18 <font>F</font> -Labelled Tracers for PET Oncology and Neurology Applications. Modecular Medicine and Medicinal, 2012, , 383-459.	0.4	3
70	A microPET study of the regional distribution of $[11C]$ -PK11195 binding following temporary focal cerebral ischemia in the rat. Correlation with post mortem mapping of microglia activation. Neurolmage, 2012, 59, 2007-2016.	4.2	30
71	PET radiotracers for molecular imaging in the brain: Past, present and future. NeuroImage, 2012, 61, 363-370.	4.2	83
72	Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. Neurolmage, 2012, 60, 902-910.	4.2	73
73	Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: A PET study with the TSPO molecular imaging biomarker [C]vinpocetine. Journal of the Neurological Sciences, 2012, 320, 110-117.	0.6	81
74	Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5795-5800.	2.2	11

#	ARTICLE	IF	CITATIONS
75	An Automated Method to Quantify Microglia Morphology and Application to Monitor Activation State Longitudinally In Vivo. PLoS ONE, 2012, 7, e31814.	2.5	205
76	Synthesis and Biological Evaluation of 4-Phenylquinazoline-2-carboxamides Designed as a Novel Class of Potent Ligands of the Translocator Protein. Journal of Medicinal Chemistry, 2012, 55, 4506-4510.	6.4	36
77	The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 811-823.	6.4	80
78	Translocator Protein (18 kDa) as a Target for Novel Anxiolytics with a Favourable Sideâ€Effect Profile. Journal of Neuroendocrinology, 2012, 24, 82-92.	2.6	65
79	Fully automated synthesis of PET TSPO radioligands [11C]DAA1106 and [18F]FEDAA1106. Applied Radiation and Isotopes, 2012, 70, 965-973.	1.5	50
80	[18F]GE-180: A novel fluorine-18 labelled PET tracer for imaging Translocator protein 18kDa (TSPO). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1308-1313.	2.2	113
81	Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews, 2012, 36, 1188-1216.	6.1	56
82	Intrathecal cannabilactone CB2R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain, 2012, 153, 1091-1106.	4.2	86
83	Synthesis of fluorine-18-labelled TSPO ligands for imaging neuroinflammation with Positron Emission Tomography. Journal of Fluorine Chemistry, 2012, 134, 107-114.	1.7	19
84	[11C]DAC-PET for Noninvasively Monitoring Neuroinflammation and Immunosuppressive Therapy Efficacy in Rat Experimental Autoimmune Encephalomyelitis Model. Journal of NeuroImmune Pharmacology, 2012, 7, 231-242.	4.1	17
85	Positron Emission Tomography in Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2012, 5, 11-21.	2.4	2
86	Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Into Imaging, 2012, 3, 111-119.	3.4	115
87	Molecular imaging of microglia/macrophages in the brain. Glia, 2013, 61, 10-23.	4.9	160
88	Targeting of the Translocator Protein 18 kDa (TSPO): A Valuable Approach for Nuclear and Optical Imaging of Activated Microglia. Bioconjugate Chemistry, 2013, 24, 1415-1428.	3.6	52
89	Imaging of carrageenan-induced local inflammation and adjuvant-induced systemic arthritis with [11C]PBR28 PET. Nuclear Medicine and Biology, 2013, 40, 906-911.	0.6	20
90	In vitro targeting and imaging the translocator protein TSPO 18-kDa through G(4)-PAMAM–FITC labeled dendrimer. Journal of Controlled Release, 2013, 172, 1111-1125.	9.9	52
91	Imaging of Neuroinflammation in Parkinsonian Syndromes with Positron Emission Tomography. Current Neurology and Neuroscience Reports, 2013, 13, 405.	4.2	8
92	Exploration of the structure–activity relationship of a novel tetracyclic class of TSPO ligands—Potential novel positron emitting tomography imaging agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2368-2372.	2.2	9

#	ARTICLE	IF	Citations
93	Structure–activity relationships of novel iodinated quinoline-2-carboxamides for targeting the translocator protein. MedChemComm, 2013, 4, 1461.	3.4	13
94	The potential of carbonâ€11 and fluorineâ€18 chemistry: illustration through the development of positron emission tomography radioligands targeting the translocator protein 18 kDa. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 96-104.	1.0	36
95	Quantification of the Specific Translocator Protein Signal of <sup>18</sup> F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. Journal of Nuclear Medicine, 2013, 54, 1915-1923.	5.0	105
96	Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy. Neurotherapeutics, 2013, 10, 111-123.	4.4	25
97	Synthesis and characterization of an MRI Gdâ€based probe designed to target the translocator protein. Magnetic Resonance in Chemistry, 2013, 51, 116-122.	1.9	7
98	[11C]PK11195 PET imaging of spinal glial activation after nerve injury in rats. Neurolmage, 2013, 79, 121-128.	4.2	32
99	Positron-Emission Tomography Imaging of the TSPO with [ <sup>18</sup> F]FEPPA in a Preclinical Breast Cancer Model. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 254-259.	1.0	17
100	Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 8891-8897.	3.6	125
101	Neuroimaging biomarkers for epilepsy: Advances and relevance to glial cells. Neurochemistry International, 2013, 63, 712-718.	3.8	10
102	InÂvivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 47-52.	2.2	185
103	Ultra-Sensitive Molecular MRI of Vascular Cell Adhesion Molecule-1 Reveals a Dynamic Inflammatory Penumbra After Strokes. Stroke, 2013, 44, 1988-1996.	2.0	92
104	In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain, 2013, 136, 2228-2238.	7.6	280
105	Propofol Decreases In Vivo Binding of <sup>11</sup> C-PBR28 to Translocator Protein (18 kDa) in the Human Brain. Journal of Nuclear Medicine, 2013, 54, 64-69.	5.0	30
106	Metabolism and Quantification of [ <sup>18</sup> F]DPA-714, a New TSPO Positron Emission Tomography Radioligand. Drug Metabolism and Disposition, 2013, 41, 122-131.	3.3	61
107	Optimisation of synthesis, purification and reformulation of (R)-[N-Methyl-11C]PK11195 for in vivo PET imaging studies., 2013,,.		1
108	Central Nervous System Expression and PET Imaging of the Translocator Protein in Relapsing–Remitting Experimental Autoimmune Encephalomyelitis. Journal of Nuclear Medicine, 2013, 54, 291-298.	5.0	34
109	PET Reveals Inflammation around Calcified Taenia solium Granulomas with Perilesional Edema. PLoS ONE, 2013, 8, e74052.	2.5	41
110	Neuroinflammation after intracerebral hemorrhage. Frontiers in Cellular Neuroscience, 2014, 8, 388.	3.7	259

#	ARTICLE	IF	Citations
111	Longitudinal PET Imaging of Muscular Inflammation Using <sup> 18 </sup> F-DPA-714 and <sup> F-Alfatide II and Differentiation with Tumors. Theranostics, 2014, 4, 546-555.</sup>	10.0	45
112	lmaging Neuroinflammation – from Bench to Bedside. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	18
113	Determination of [ <sup>11</sup> C]PBR28 Binding Potential <i>in vivo:</i> A First Human TSPO Blocking Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 989-994.	4.3	117
114	Kinetic Modeling without Accounting for the Vascular Component Impairs the Quantification of [ <sup>11</sup> C]PBR28 Brain PET Data. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1060-1069.	4.3	112
115	The 18 <scp>kDa</scp> Translocator Protein, Microglia and Neuroinflammation. Brain Pathology, 2014, 24, 631-653.	4.1	182
116	Positron Emission Tomography Molecular Imaging in Late-Life Depression. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 13-23.	2.3	10
117	Synthesis and evaluation of new $<$ sup $>$ 18 $<$ /sup $>$ F-labelled acetamidobenzoxazolone-based radioligands for imaging of the translocator protein (18 kDa, TSPO) in the brain. Organic and Biomolecular Chemistry, 2014, 12, 9621-9630.	2.8	29
118	Translocator protein (18ÂkDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. Journal of Neuroinflammation, 2014, 11, 3.	7.2	177
119	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. NeuroImage, 2014, 84, 868-875.	4.2	56
120	Preparation and evaluation of novel pyrazolo [1,5-a] pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18kDa with PET. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1550-1556.	2.2	38
121	Immunological Mechanisms and Therapies in Brain Injuries and Stroke. , 2014, , .		4
122	Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. Journal of NeuroVirology, 2014, 20, 219-232.	2.1	78
123	Characterization of a novel acetamidobenzoxazoloneâ€based PET ligand for translocator protein (18ÂkDa) imaging of neuroinflammation in the brain. Journal of Neurochemistry, 2014, 129, 712-720.	3.9	39
124	[ <sup>18</sup> F]DPAâ€C5yne, a novel fluorineâ€18â€labelled analogue of DPAâ€714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 410-418.	1.0	11
125	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with <sup>18</sup> F-PBR111 PET. Journal of Nuclear Medicine, 2014, 55, 1112-1118.	5.0	82
126	Development of <i>N</i> -Methyl-(2-arylquinolin-4-yl)oxypropanamides as Leads to PET Radioligands for Translocator Protein (18 kDa). Journal of Medicinal Chemistry, 2014, 57, 6240-6251.	6.4	21
127	Synthesis and Evaluation of Translocator 18 kDa Protein (TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding Sensitivity to Human Single Nucleotide Polymorphism rs6971. ACS Chemical Neuroscience, 2014, 5, 963-971.	3.5	91
128	Preventing Vascular Effects on Brain Injury and Cognition Late in Life: Knowns and Unknowns. Neuropsychology Review, 2014, 24, 371-387.	4.9	15

#	Article	IF	CITATIONS
129	Neuroimaging in repetitive brain trauma. Alzheimer's Research and Therapy, 2014, 6, 10.	6.2	49
130	Detection of Microglial Activation in an Acute Model of Neuroinflammation Using PET and Radiotracers <sup>11</sup> C-( <i>R</i> )-PK11195 and <sup>18</sup> F-GE-180. Journal of Nuclear Medicine, 2014, 55, 466-472.	5.0	127
131	[18F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model. Arthritis Research and Therapy, 2014, 16, R69.	3.5	24
132	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research and Therapy, 2014, 16, R70.	3.5	32
133	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurology, The, 2014, 13, 807-822.	10.2	197
135	[ <sup>18</sup> F]Fluoromethyl-PBR28 as a Potential Radiotracer for TSPO: Preclinical Comparison with [ <sup>11</sup> C]PBR28 in a Rat Model of Neuroinflammation. Bioconjugate Chemistry, 2014, 25, 442-450.	3.6	33
136	An improved, regioselective synthesis of the radiolabelling precursor for the translocator protein targeting positron emission tomography imaging radiotracer [18F]GE-180. Tetrahedron Letters, 2014, 55, 5141-5143.	1.4	3
137	Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 283-287.	2.2	32
138	In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer <sup>18</sup> F-FEDAA1106. Molecular Imaging, 2014, 13, 7290.2014.00014.	1.4	32
139	Utility of $18\hat{a}\in\%$ F-FDG and $11\text{C-PBR28}$ microPET for the assessment of rat aortic aneurysm inflammation. EJNMMI Research, 2014, 4, 20.	2.5	15
140	[ <sup>18</sup> F]FPBMP: – a potential new positron emission tomography radioligand for imaging of translocator protein (18 kDa) in peripheral organs of rats. RSC Advances, 2015, 5, 101447-101454.	3.6	16
141	The methodology of TSPO imaging with positron emission tomography. Biochemical Society Transactions, 2015, 43, 586-592.	3.4	186
142	TSPO as a target for glioblastoma therapeutics. Biochemical Society Transactions, 2015, 43, 531-536.	3.4	24
143	Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection. Biochemical Society Transactions, 2015, 43, 559-565.	3.4	32
145	The impact of the rs6971 polymorphism in TSPO for quantification and study design. Clinical and Translational Imaging, 2015, 3, 417-422.	2.1	28
146	TSPO imaging in stroke: from animal models to human subjects. Clinical and Translational Imaging, 2015, 3, 423-435.	2.1	14
147	Targeting translocator protein (18ÂkDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration. Journal of Neuroinflammation, 2015, 12, 201.	7.2	93
148	Conformational Flexibility in the Transmembrane Protein TSPO. Chemistry - A European Journal, 2015, 21, 16555-16563.	3.3	23

#	Article	IF	CITATIONS
149	Efficient tritiation of the translocator protein (18 kDa) selective ligand DPAâ€₹14. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 1-6.	1.0	14
150	[ <sup>18</sup> F]FEBMP: Positron Emission Tomography Imaging of TSPO in a Model of Neuroinflammation in Rats, and <i>in vitro</i> Autoradiograms of the Human Brain. Theranostics, 2015, 5, 961-969.	10.0	45
151	Elusive roles for reactive astrocytes in neurodegenerative diseases. Frontiers in Cellular Neuroscience, 2015, 9, 278.	3.7	327
152	Radiotracers Used for the Scintigraphic Detection of Infection and Inflammation. Scientific World Journal, The, 2015, 2015, 1-33.	2.1	23
153	Radiosynthesis, <i>In Vivo </i> Biological Evaluation, and Imaging of Brain Lesions with [ <sup><b>123</b></sup>  -CLINME, a New SPECT Tracer for the Translocator Protein. Disease Markers, 2015, 2015, 1-11.	1.3	7
154	A novel <sup>18</sup> F-labelled high affinity agent for PET imaging of the translocator protein. Chemical Science, 2015, 6, 4772-4777.	7.4	17
155	Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [18F]GE-180. Nuclear Medicine and Biology, 2015, 42, 711-719.	0.6	17
156	Omega-3 fatty acids prevent LPS-induced passive avoidance learning and memory and CaMKII-α gene expression impairments in hippocampus of rat. Pharmacological Reports, 2015, 67, 370-375.	3.3	32
157	In vivo imaging and characterization of [18F]DPA-714, a potential new TSPO ligand, in mouse brain and peripheral tissues using small-animal PET. Nuclear Medicine and Biology, 2015, 42, 309-316.	0.6	57
158	Identification of a Key Cholesterol Binding Enhancement Motif in Translocator Protein 18 kDa. Biochemistry, 2015, 54, 1441-1443.	2.5	27
159	The Role of Neuroinflammation in Dementias. Current Neurology and Neuroscience Reports, 2015, 15, 17.	4.2	112
160	[18F]DPA-714 PET imaging of translocator protein TSPO (18ÂkDa) in the normal and excitotoxically-lesioned nonhuman primate brain. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 478-494.	6.4	45
161	18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 503-511.	6.4	109
162	Molecular imaging of inflammation in the ApoE -/- mouse model of atherosclerosis with IodoDPA. Biochemical and Biophysical Research Communications, 2015, 461, 70-75.	2.1	29
163	Synthesis and inÂvitro characterization of novel fluorinated derivatives of the TSPO 18ÂkDa ligand SSR180575. European Journal of Medicinal Chemistry, 2015, 101, 736-745.	5.5	8
164	PET Imaging of Translocator Protein (18 kDa) in a Mouse Model of Alzheimer's Disease Using <i>N</i> -(2,5-Dimethoxybenzyl)-2- <sup>18</sup> F-Fluoro- <i>N</i> -(2-Phenoxyphenyl)Acetamide. Journal of Nuclear Medicine, 2015, 56, 311-316.	5.0	47
165	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain, 2015, 138, 2687-2700.	7.6	168
166	In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. Molecular Psychiatry, 2015, 20, 1579-1587.	7.9	101

#	Article	IF	CITATIONS
167	Quantification of [ <sup>18</sup> F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 766-772.	4.3	99
168	Roles of microglia in brain development, tissue maintenance and repair. Brain, 2015, 138, 1138-1159.	7.6	316
169	Evaluation of [11C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1106-1118.	6.4	14
170	Synthesis of [11C]GSK1482160 as a new PET agent for targeting P2X7 receptor. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1965-1970.	2.2	69
171	<i>In Vivo</i> PET Imaging of the $\hat{1}\pm4\hat{1}^2$ 2 Nicotinic Acetylcholine Receptor As a Marker for Brain Inflammation after Cerebral Ischemia. Journal of Neuroscience, 2015, 35, 5998-6009.	3.6	41
172	Minireview: Translocator Protein (TSPO) and Steroidogenesis: A Reappraisal. Molecular Endocrinology, 2015, 29, 490-501.	3.7	63
173	PET in Multiple Sclerosis. Clinical Nuclear Medicine, 2015, 40, e46-e52.	1.3	20
174	Advanced imaging tools to investigate multiple sclerosis pathology. Presse Medicale, 2015, 44, e159-e167.	1.9	19
175	The changing landscape in translocator protein (TSPO) function. Trends in Endocrinology and Metabolism, 2015, 26, 341-348.	7.1	103
176	Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis. Expert Opinion on Drug Discovery, 2015, 10, 557-570.	5.0	27
177	Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease. Trends in Neurosciences, 2015, 38, 621-636.	8.6	134
178	Anti-stress effects of ONO-2952, a novel translocator protein 18ÂkDaÂantagonist, in rats. Neuropharmacology, 2015, 99, 51-66.	4.1	17
179	<i>In Vivo</i> Detection of Age- and Disease-Related Increases in Neuroinflammation by <sup>18</sup> F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice. Journal of Neuroscience, 2015, 35, 15716-15730.	3.6	110
180	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease, 2015, 74, 58-65.	4.4	208
181	Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes. Frontiers in Molecular Neuroscience, 2016, 9, 85.	2.9	19
182	Imaging Chronic Traumatic Encephalopathy: A Biomedical Engineering Perspective. Critical Reviews in Biomedical Engineering, 2016, 44, 473-492.	0.9	0
183	Recent advances in mesoscopic-scale imaging in animal models of ischemic stroke. Current Opinion in Neurology, 2016, 29, 104-111.	3.6	6
184	Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. Molecular Imaging, 2016, 15, 153601211663918.	1.4	15

#	Article	IF	CITATIONS
185	A Novel PET Imaging Probe for the Detection and Monitoring of Translocator Protein 18 kDa Expression in Pathological Disorders. Scientific Reports, 2016, 6, 20422.	3.3	44
186	Design, synthesis and biological evaluation of methyl-2-(2-(5-bromo) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 114491-114499.	50 707 Td 3.6	(benzoxaz <mark>olo</mark> 12
187	Contrast Media. , 2016, , 59-70.		1
188	Pharmacokinetic Analysis of <sup>11</sup> C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with ( <i>R</i> )- <sup>11</sup> C-PK11195. Journal of Nuclear Medicine, 2016, 57, 785-791.	5.0	21
189	In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Translational Psychiatry, 2016, 6, e777-e777.	4.8	134
190	Three Month Follow-Up of Rat Mild Traumatic Brain Injury: A Combined [ <sup>18</sup> F]FDG and [ <sup>11</sup> C]PK11195 Positron Emission Study. Journal of Neurotrauma, 2016, 33, 1855-1865.	3.4	22
191	In vivo PET imaging of the neuroinflammatory response in rat spinal cord injury using the TSPO tracer [18F]GE-180 and effect of docosahexaenoic acid. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1710-1722.	6.4	24
192	TSPO imaging in parkinsonian disorders. Clinical and Translational Imaging, 2016, 4, 183-190.	2.1	56
193	Neuroimaging Biomarkers in Alzheimer's Disease. , 2016, , 51-100.		8
194	Discovery of a fluorinated 4â€oxoâ€quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. Journal of Neurochemistry, 2016, 138, 874-886.	3.9	31
195	Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1–Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using <sup>11</sup> C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. Journal of Nuclear Medicine, 2016, 57, 1905-1912.	5.0	18
196	Genetic and degenerative disorders primarily causing dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 525-564.	1.8	5
197	Flutriciclamide ( <sup>18</sup> F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine, 2016, 57, 1753-1759.	5.0	93
198	Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking. Brain Structure and Function, 2016, 221, 1279-1290.	2.3	49
199	In vivo imaging of neuroinflammation in schizophrenia. Schizophrenia Research, 2016, 173, 200-212.	2.0	118
200	Neuroinflammation in treated HIV-positive individuals. Neurology, 2016, 86, 1425-1432.	1.1	136
201	Evaluation of PET Imaging Performance of the TSPO Radioligand [18F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation. Molecular Imaging and Biology, 2016, 18, 127-134.	2.6	12
202	PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 895-902.	6.4	22

#	Article	IF	Citations
203	Microglial activation in Parkinson's disease using [18F]-FEPPA. Journal of Neuroinflammation, 2017, 14, 8.	7.2	88
204	Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 Positron Emission Tomography Study. Neuropsychopharmacology, 2017, 42, 1630-1639.	5.4	47
205	Neuroinflammation in Neurodegenerative Disorders—a Review. Current Neurology and Neuroscience Reports, 2017, 17, 25.	4.2	240
206	In vivo imaging of translocator protein, a marker of activated microglia, in alcohol dependence. Molecular Psychiatry, 2017, 22, 1759-1766.	7.9	64
207	Development of a <sup>18</sup> F-Labeled Radiotracer with Improved Brain Kinetics for Positron Emission Tomography Imaging of Translocator Protein (18 kDa) in Ischemic Brain and Glioma. Journal of Medicinal Chemistry, 2017, 60, 4047-4061.	6.4	22
208	Imaging in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 233-274.	2.0	21
209	Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Multiple Sclerosis and Related Disorders, 2017, 15, 27-33.	2.0	25
210	Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 42-47.	2.0	28
211	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. JAMA Neurology, 2017, 74, 67.	9.0	134
212	Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology, 2017, 56, 1837-1846.	1.9	22
213	A Facile Radiolabeling of [ <sup>18</sup> F]FDPA via Spirocyclic Iodonium Ylides: Preliminary PET Imaging Studies in Preclinical Models of Neuroinflammation. Journal of Medicinal Chemistry, 2017, 60, 5222-5227.	6.4	43
214	Quantification of ONO-2952 Occupancy of 18-kDaTranslocator Protein in Conscious Monkey Brains using Positron Emission Tomography. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 457-465.	2.5	6
215	Aromatase and neuroinflammation in rat focal brain ischemia. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 225-233.	2.5	15
216	PET imaging of the neurovascular interface in cerebrovascular disease. Nature Reviews Neurology, 2017, 13, 676-688.	10.1	38
217	[11C]-(R)-PK11195 positron emission tomography in patients with complex regional pain syndrome. Medicine (United States), 2017, 96, e5735.	1.0	40
218	Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases. Nuclear Medicine and Molecular Imaging, 2017, 51, 283-296.	1.0	80
219	18-kDa translocator protein ligand 18F-FEMPA: Biodistribution and uptake into atherosclerotic plaques in mice. Journal of Nuclear Cardiology, 2017, 24, 862-871.	2.1	39
220	Derivatives of the pyrazolo[1,5- a ]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. European Journal of Pharmaceutical Sciences, 2017, 96, 186-192.	4.0	12

#	Article	IF	Citations
221	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.4	12
222	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology, 2017, 19, 77-89.	2.6	58
223	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [ <sup>11</sup> C]DPA-713 positron emission tomography. Lupus, 2017, 26, 170-178.	1.6	25
224	Targeting Neuroinflammation to Treat Alzheimer's Disease. CNS Drugs, 2017, 31, 1057-1082.	5.9	182
225	[ <sup>18</sup> F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer's Disease. Theranostics, 2017, 7, 1422-1436.	10.0	64
226	Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2017, 18, 785.	4.1	133
227	In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [18F]GE180-PET Study. Frontiers in Neurology, 2017, 8, 665.	2.4	15
228	TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?. Contrast Media and Molecular Imaging, 2017, 2017, 1-17.	0.8	32
229	Molecular Imaging of Neuroinflammation in Neurodegenerative Dementias: The Role of In Vivo PET Imaging. International Journal of Molecular Sciences, 2017, 18, 993.	4.1	64
230	Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations. International Journal of Molecular Sciences, 2017, 18, 802.	4.1	101
231	The emerging role of PET imaging in dementia. F1000Research, 2017, 6, 1830.	1.6	43
232	Evaluation of the novel TSPO radiotracer		

#	Article	IF	CITATIONS
239	Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET. European Journal of Medicinal Chemistry, 2018, 159, 292-306.	<b>5.</b> 5	13
240	Effect of overnight smoking abstinence on a marker for microglial activation: a [11C]DAA1106 positron emission tomography study. Psychopharmacology, 2018, 235, 3525-3534.	3.1	23
241	Molecular Imaging of Neuroinflammation in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 347-363.	2.0	15
242	Synthesis of two novel [18F]fluorobenzene-containing radiotracers via spirocyclic iodonium ylides and positron emission tomography imaging of translocator protein (18 kDa) in ischemic brain. Organic and Biomolecular Chemistry, 2018, 16, 8325-8335.	2.8	7
243	Influence of alcoholism and cholesterol on TSPO binding in brain: PET [11C]PBR28 studies in humans and rodents. Neuropsychopharmacology, 2018, 43, 1832-1839.	5.4	57
244	Positron Emission Tomography Imaging of Macrophages in Atherosclerosis with <sup>18</sup> F-GE-180, a Radiotracer for Translocator Protein (TSPO). Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.8	27
245	PET/CT of Dementia. American Journal of Roentgenology, 2018, 211, 246-259.	2.2	18
246	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. Advances in Pharmacology, 2018, 82, 163-185.	2.0	32
247	Role of Neuroinflammation in the Trajectory of Alzheimer's Disease and in vivo Quantification Using PET. Journal of Alzheimer's Disease, 2018, 64, S339-S351.	2.6	32
248	In vivo Imaging of Glial Activation in Alzheimer's Disease. Frontiers in Neurology, 2018, 9, 625.	2.4	71
249	Automated Synthesis of ( <i>rac</i> )â€, ( <i>R</i> )â€, and ( <i>S</i> )â€( <sup>18</sup> F]Epifluorohydrin and Their Application for Developing PET Radiotracers Containing a 3â€( <sup>18</sup> F]Fluoroâ€2â€hydroxypropyl Moiety. ChemMedChem, 2018, 13, 1723-1731.	3.2	6
250	Preclinical comparison study between [18F]fluoromethyl-PBR28 and its deuterated analog in a rat model of neuroinflammation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2925-2929.	2.2	15
251	Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability. Brain Pathology, 2018, 28, 723-734.	4.1	19
252	[18F]DAA1106: Automated radiosynthesis using spirocyclic iodonium ylide and preclinical evaluation for positron emission tomography imaging of translocator protein (18†kDa). Bioorganic and Medicinal Chemistry, 2018, 26, 4817-4822.	3.0	16
253	TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31. Human Molecular Genetics, 2018, 27, 2893-2912.	2.9	33
254	Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma. Molecular Imaging and Biology, 2019, 21, 113-121.	2.6	14
255	<sup>11</sup> C-DPA-713 Versus <sup>18</sup> F-GE-180: A Preclinical Comparison of Translocator Protein 18 kDa PET Tracers to Visualize Acute and Chronic Neuroinflammation in a Mouse Model of Ischemic Stroke. Journal of Nuclear Medicine, 2019, 60, 122-128.	5.0	46
256	Brain Metabolites and Peripheral Biomarkers Associated with Neuroinflammation in Complex Regional Pain Syndrome Using [11C]-(R)-PK11195 Positron Emission Tomography and Magnetic Resonance Spectroscopy: A Pilot Study. Pain Medicine, 2019, 20, 504-514.	1.9	19

#	Article	IF	CITATIONS
257	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2831-2847.	6.4	45
258	Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamide. Bioorganic and Medicinal Chemistry, 2019, 27, 4069-4080.	3.0	11
259	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161.	4.1	173
260	Characterisation of the ligand binding sites in the translocator protein TSPO using the chimeric bacterial-mammalian constructs. Protein Expression and Purification, 2019, 164, 105456.	1.3	6
261	Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Human Brain Mapping, 2019, 40, 5424-5442.	3.6	127
262	Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region. Neurolmage, 2019, 188, 102-110.	4.2	18
263	Kinetic modelling and quantification bias in small animal PET studies with [18F]AB5186, a novel 18 kDa translocator protein radiotracer. PLoS ONE, 2019, 14, e0217515.	2.5	8
264	A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
265	PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases. Current Neurology and Neuroscience Reports, 2019, 19, 38.	4.2	19
266	Translocator protein localises to CD11b+ macrophages in atherosclerosis. Atherosclerosis, 2019, 284, 153-159.	0.8	15
267	New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Current Neurology and Neuroscience Reports, 2019, 19, 24.	4.2	61
268	18F-PBR06 PET/CT imaging for evaluating atherosclerotic plaques linked to macrophage infiltration. Nuclear Medicine Communications, 2019, 40, 370-376.	1.1	6
270	Neuroimaging Biomarkers of Experimental Epileptogenesis and Refractory Epilepsy. International Journal of Molecular Sciences, 2019, 20, 220.	4.1	42
271	<i>In vivo</i> molecular imaging of neuroinflammation in Alzheimer's disease. Journal of Neurochemistry, 2019, 149, 438-451.	3.9	70
272	Hypothalamic Inflammation at a Crossroad of Somatic Diseases. Cellular and Molecular Neurobiology, 2019, 39, 11-29.	3.3	13
273	The folate receptor $\hat{l}^2$ as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis. Drug Delivery and Translational Research, 2019, 9, 366-378.	5.8	78
274	In vivo monitoring of remnant undifferentiated neural cells following human induced pluripotent stem cell-derived neural stem/progenitor cells transplantation. Stem Cells Translational Medicine, 2020, 9, 465-477.	3.3	24
275	A concisely automated synthesis of TSPO radiotracer [ $\langle \sup \rangle 18 \langle \sup \rangle F$ ]FDPA based on spirocyclic iodonium ylide method and validation for human use. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 119-128.	1.0	10

#	Article	IF	CITATIONS
276	Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy. Journal of NeuroImmune Pharmacology, 2020, 15, 694-714.	4.1	12
277	PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714. Frontiers in Neuroscience, 2020, 14, 810.	2.8	16
278	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry,the, 2020, 7, 1064-1074.	7.4	149
279	Radionuclide Imaging of the Molecular Mechanisms Linking Heart and Brain in Ischemic Syndromes. Circulation: Cardiovascular Imaging, 2020, 13, .	2.6	4
280	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 2020, 207, 112725.	5 <b>.</b> 5	4
281	Microglial Dysregulation and Suicidality: A Stress-Diathesis Perspective. Frontiers in Psychiatry, 2020, 11, 781.	2.6	15
282	Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [11C]N′-MPB for visualization of 18 kDa TSPO in brain. New Journal of Chemistry, 2020, 44, 7912-7922.	2.8	12
283	AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. Frontiers in Neurology, 2020, 11, 459.	2.4	11
284	[18F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2602-2612.	6.4	20
285	Visualization of translocator protein (18ÂkDa) (TSPO) in the retina of diabetic retinopathy rats using fluorine-18-DPA-714. Annals of Nuclear Medicine, 2020, 34, 675-681.	2.2	4
286	Reliable quantification of 18F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2887-2900.	6.4	10
287	Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update. Cells, 2020, 9, 870.	4.1	49
288	An update into the medicinal chemistry of translocator protein (TSPO) ligands. European Journal of Medicinal Chemistry, 2021, 209, 112924.	5.5	31
289	Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with <sup>18</sup> F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism. Journal of Nuclear Medicine, 2021, 62, 536-544.	5.0	31
290	PET imaging in HIV patients. , 2021, , .		0
291	Central Nervous System Molecular Imaging. , 2021, , 1261-1285.		0
292	Identifying Musculoskeletal Pain Generators Using Molecular Imaging. , 2021, , 1373-1392.		0
293	Enhancing glucose metabolism via gluconeogenesis is therapeutic in a zebrafish model of Dravet syndrome. Brain Communications, 2021, 3, fcab004.	3.3	14

#	Article	IF	CITATIONS
294	The Interplay of Cholesterol and Ligand Binding in hTSPO from Classical Molecular Dynamics Simulations. Molecules, 2021, 26, 1250.	3.8	5
295	Mapping of Translocator Protein (18 kDa) in Peripheral Sterile Inflammatory Disease and Cancer through PET Imaging. Molecular Pharmaceutics, 2021, 18, 1507-1529.	4.6	9
296	Imaging of the glioma microenvironment by TSPO PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 174-185.	6.4	24
297	Determination of Hybrid TSPO Ligands with Minimal Impact of SNP (rs6971) through Molecular Docking and MD Simulation Study. Letters in Drug Design and Discovery, 2022, 19, 549-563.	0.7	2
298	Microglia as therapeutic targets after neurological injury: strategy for cell therapy. Expert Opinion on Therapeutic Targets, 2021, 25, 365-380.	3.4	22
299	Construction of dimeric hTSPO protein model using homology modeling and molecular dynamics. Journal of Physics: Conference Series, 2021, 1932, 012016.	0.4	1
300	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	2.4	11
301	Contribution of TSPO imaging in the understanding of the state of gliosis in substance use disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 186-200.	6.4	5
302	What value can TSPO PET bring for epilepsy treatment?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 221-233.	6.4	11
303	Optimization of reconstruction parameters in [18F]FDG PET brain images aiming scan time reduction. Revista Brasileira De FÃsica Médica, 0, 15, 611.	0.0	1
304	Exploring Translocator Protein (TSPO) Medicinal Chemistry: An Approach for Targeting Radionuclides and Boron Atoms to Mitochondria. Journal of Medicinal Chemistry, 2021, 64, 9649-9676.	6.4	2
305	Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 201-220.	6.4	23
306	Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 137-145.	6.4	5
307	Positron Emission Tomography Techniques to Measure Active Inflammation, Fibrosis and Angiogenesis: Potential for Non-invasive Imaging of Hypertensive Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 719031.	2.4	9
308	Translation of 11C-labeled tracer synthesis to a CGMP environment as exemplified by [11C]ER176 for PET imaging of human TSPO. Nature Protocols, 2021, 16, 4419-4445.	12.0	7
309	Alternative strategies for the synthesis of [11C]ER176 for PET imaging of neuroinflammation. Applied Radiation and Isotopes, 2021, 178, 109954.	1.5	4
310	Synthesis and pharmacological evaluation of [ <sup>18</sup> F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971. RSC Medicinal Chemistry, 2021, 12, 1207-1221.	3.9	7
311	TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis. Seminars in Neurology, 2017, 37, 546-557.	1.4	9

#	Article	IF	CITATIONS
312	A depth-encoding PET detector for high resolution PET using $1\ \mathrm{mm}$ SiPMs. Physics in Medicine and Biology, 2020, 65, 165011.	3.0	7
313	[18F]DPA-714: Direct Comparison with [11C]PK11195 in a Model of Cerebral Ischemia in Rats. PLoS ONE, 2013, 8, e56441.	2.5	77
314	The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory 'M1' human macrophages. PLoS ONE, 2017, 12, e0185767.	2.5	59
315	PET Radioligands for In Vivo Visualization of Neuroinflammation. Current Pharmaceutical Design, 2014, 20, 5897-5913.	1.9	42
316	Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease. Current Vascular Pharmacology, 2015, 13, 218-222.	1.7	19
317	MRI Assessment of Post-Ischemic Neuroinflammation in Stroke: Experimental and Clinical Studies., 0,,.		1
318	Assessment of Neuroinflammation in Transferred EAE Via a Translocator Protein Ligand. , 0, , .		1
319	TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. Neuromethods, 2022, , 407-427.	0.3	2
320	Alteration of neuroinflammation detected by 18F-GE180 PET imaging in place-conditioned rats with morphine withdrawal. EJNMMI Research, 2021, 11, 103.	2.5	2
322	Inflammation in Parkinson's Disease: Causes and Consequences. , 0, , .		0
323	In Vivo Imaging of Neuroinflammation in Acute Brain Injury. , 2014, , 235-248.		0
325	Nuclear Medicine Imaging Tracers for Neurology. , 2014, , 3-30.		1
326	PET Imaging in Multiple Sclerosis: Focus on the Translocator Protein., 2014,, 757-773.		1
327	Semiquantification Study of [11C]-(R)-PK11195 PET Brain Images in Multiple Sclerosis. Revista Brasileira De FÃsica Médica, 2017, 10, 39.	0.0	1
328	Multimodality Preclinical Imaging in Inflammatory Diseases. , 2019, , 135-160.		0
330	Imaging translocator protein expression with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 74.	6.4	4
331	Nuclear Medicine Imaging Tracers for Neurology. , 2021, , 3-35.		2
333	Current imaging strategies in rheumatoid arthritis. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 174-220.	1.0	33

#	Article	IF	CITATIONS
334	An automated radiosynthesis of [18F]DPA-714 on a commercially available radiosynthesizer, Elixys Flex/Chem. Applied Radiation and Isotopes, 2022, 180, 110032.	1.5	3
336	Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising <sup>18</sup> F-Labeled Ligand. Journal of Medicinal Chemistry, 2021, 64, 16731-16745.	6.4	15
337	Huntington's Disease. , 2022, , 411-419.		1
338	InÂVivo Evaluation of 6 Analogs of <sup>11</sup> C-ER176 as Candidate <sup>18</sup> F-Labeled Radioligands for 18-kDa Translocator Protein. Journal of Nuclear Medicine, 2022, 63, 1252-1258.	5.0	10
339	Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: An update. European Journal of Neuroscience, 2022, 55, 1322-1343.	2.6	27
340	[18F]DPA-714 PET imaging for the quantitative evaluation of early spatiotemporal changes of neuroinflammation in rat brain following status epilepticus. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2265-2275.	6.4	10
341	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. Current Medicinal Chemistry, 2022, 29, 4862-4890.	2.4	9
342	The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Molecular Neurodegeneration, 2022, 17, 22.	10.8	24
343	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. Neuropsychopharmacology, 2022, 47, 1421-1427.	5.4	10
344	Efficient and automatic synthesis of TSPO PET ligand [18F]-GE-180 and its application in rheumatoid arthritis model. Applied Radiation and Isotopes, 2022, 184, 110213.	1.5	1
345	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. Journal of Neurochemistry, 2023, 164, 364-400.	3.9	7
346	Neuroinflammation in Low-Level PM2.5-Exposed Rats Illustrated by PET via an Improved Automated Produced [ <sup>18</sup> F]FEPPA: A Feasibility Study. Molecular Imaging, 2022, 2022, .	1.4	1
347	18F-Radiolabeled Translocator Protein (TSPO) PET Tracers: Recent Development of TSPO Radioligands and Their Application to PET Study. Pharmaceutics, 2022, 14, 2545.	4.5	10
348	Diverse Effects of Hypothalamic Proline-Rich Peptide (PRP-1) on Cell Death in Neurodegenerative and Cancer Diseases. Biochemistry, 0, , .	1.2	0
349	Potential of [11C](R)-PK11195 PET Imaging for Evaluating Tumor Inflammation: A Murine Mammary Tumor Model. Pharmaceutics, 2022, 14, 2715.	4.5	0
350	Molecular Imaging of Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment. Advances in Experimental Medicine and Biology, 2023, , 301-326.	1.6	0
351	Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia. NeuroImage: Clinical, 2023, 38, 103373.	2.7	0
353	Aiming for [18F]FDG-PET acquisition time reduction in clinical practice for neurological patients. Physica Medica, 2023, 112, 102604.	0.7	0

## CITATION REPORT

#	ARTICLE	IF	CITATIONS
354	Imaging Modalities and Their Findings in Patients With Complex Regional Pain Syndrome: A Review. Cureus, 2023, , .	0.5	0
355	Neuroinflammation is linked to dementia risk in Parkinson's disease. Brain, 2024, 147, 923-935.	7.6	2
356	Concussion: Beyond the Cascade. Cells, 2023, 12, 2128.	4.1	3
357	Up-and-coming Radiotracers for Imaging Pain Generators. Seminars in Musculoskeletal Radiology, 2023, 27, 661-675.	0.7	O
358	Functional role of translocator protein and its ligands in ocular diseases (Review). Molecular Medicine Reports, 2024, 29, .	2.4	0
359	A first-in-man study of [18F] FEDAC: a novel PET tracer for the 18-kDa translocator protein. Annals of Nuclear Medicine, 2024, 38, 264-271.	2.2	0